>

JPM week 2024: NanoSyrinx highlighted in GEN

NanoSyrinx CEO Joe Healey, and CBO James Lapworth attended the JP Morgan Healthcare conference in San Francisco last week.

Among a great week of meetings with collaborators, investors and partners, they sat down with Jonathan Grinstein PhD, a writer for GEN Edge, and spoke about the journey the company had been on and the outlook for the future.

In a week of major sector announcements and crowded news airwaves, we are delighted that GEN chose to cover our story, and the full article can be read at the link below.

JPM 2024: NanoSyrinx Wields Original Bacterial Syringe IP for Protein Delivery

Read more news

Dr Valentina Galli

NanoSyrinx strengthens senior R&D team

Appointments of Dr Valentina Galli as Associate Research Director, Translational Biology, and Steve Ruscoe as Principal Scientist, Process Development Drug delivery and process development expertise further expands the Company’s R&D capabilities Coventry, UK, 21st January 2025: NanoSyrinx, a synthetic biology company developing Nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, today […]

Read more

Meet our science and scientists at SITC and EORTC

Members from the NanoSyrinx team will be on the road over the coming weeks presenting exciting data from our internal developments and recent collaborations. If you’d like to learn more about our science and meet some of the talented folks responsible for it, come along to the sessions below. A copy of the poster can […]

Read more
Dr Edwin Moses, Chairman NanoSyrinx

NanoSyrinx closes £10 million GBP financing and appoints Dr. Edwin Moses as Chairman

Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and existing investors, IQ Capital and Meltwind Appointment of Edwin Moses as Chairman to support the leadership team in maximising the value of the technology platform Novel “nanosyringe” platform can deliver complex biologic payloads selectively and […]

Read more
See more news